In summary, the results from our study provide the scientific rationale for exploring novel therapeutic approaches in targeting neuronal guidance factor/receptor interactions, such as Netrin-1/Neogenin, as a means to reduce disease progression and improve patient survival in melanoma. The gene discussed is NTN1; the disease is melanoma.